All News

RheumNow Podcast square

New Year's Resolutions (1.5.2024)

d Jack Cush, MD

Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Chinese Phase 2b RCT of telitacicept (TACI-Fc fusion protein inhibits both BAFF & APRIL) 3 doses vs PBO in 249 active SLE pts. Wk 48 SRI-4 response favored TELI (76% 240 mg, 68% 160 mg, 71% 80 mg vs 34% w/ PBO (all p<0.001) https://t.co/fz4W1le4Db https://t.co/0mTC4gQcdr

Links:

Dr. John Cush RheumNow ( View Tweet)
ild.jpg

Biomarker Predicts Survival in Autoimmune Lung Disease

d MedPage Today

One major subgroup of patients with interstitial lung disease (ILD) arising from polymyositis/dermatomyositis (PM/DM) survived significantly longer when serum levels of interferon-λ3 were relatively low, researchers found.

Read Article
Best of 2023: Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis? https://t.co/9xn7lvxPiG https://t.co/PFYUISEKLe

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/XdQ3D2McTF https://t.co/wnusToyZTG https://t.co/w8ooCCGrI0…

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/XdQ3D2McTF https://t.co/wnusToyZTG https://t.co/w8ooCCGrI0…

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/XdQ3D2McTF https://t.co/wnusToyZTG https://t.co/w8ooCCGrI0…

Links:

Dr. John Cush RheumNow ( View Tweet)

brain headache neuro

Best of 2023: Treatment and Management of Neuropsychiatric Lupus

d Eric Dein, MD

At the 2023 ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 

Read Article
CSS Storm Cytokine

Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome

d Jack Cush, MD

A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance and expert opinion on the evaluation, management and monitoring of patients with Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with the primary intent to halt disease progression and prevent life-threatening complications from HLH/MAS.

Read Article
FDA Approves Colchicine for CV Prevention. The FDA has approved colchicine for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication. https://t.co/g6j9yvl1n2 https://t.co/RUip1o4MYZ

Links:

Dr. John Cush RheumNow ( View Tweet)
MSK Syndrome from Dupilimab, an IL-4/13 Inhibitor. A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab. https://t.co/w5djtUzAGG https://t.co/eGMJQJ6Pw2

Links:

Dr. John Cush RheumNow ( View Tweet)
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/LNIqQxQFKK

Links:

Dr. John Cush RheumNow ( View Tweet)

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/vAMPWV1gKi

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/AJD4uOS9hz https://t.co/8bmyTUWyFs https://t.co/6IYjk0XUJq https://t.co/OfjdvJZciB

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/AJD4uOS9hz https://t.co/8bmyTUWyFs https://t.co/6IYjk0XUJq https://t.co/OfjdvJZciB

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/AJD4uOS9hz https://t.co/8bmyTUWyFs https://t.co/6IYjk0XUJq https://t.co/OfjdvJZciB

Links:

Dr. John Cush RheumNow ( View Tweet)
Heel, pain,enthesitis,achilles

Best of 2023: MSK Symptoms from Dupilimab, an IL-4/13 Inhibitor

d Jack Cush, MD

A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.

Read Article
lung%2Cbright.jpg

ICYMI: Effective Treatments for Rheumatoid Arthritis ILD

d Michael Putman, MD, MSCI

The American College of Rheumatology guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence.

Read Article
RheumNow Podcast square

RheumNow Podcast – Bill of Rights (12.15.2023)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery. 

Read Article

IL-18 excess is assoc. w/ autoinflammatory Dz, "IL-18opathies". High IL-18 associated w/ #MAS & PSTPIP1-related diseases (eg, PAPA syndr. Pyogenic arthritis, pyoderma gangrenosum, acne)IL-18 binding protein is a biomarker of IFNγ activity. https://t.co/dy3xHdgTXX https://t.co/qBvCHvtsu7

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.